Mary C Cambou1, José Eduardo Levi2, Jordan E Lake3, Angela de Andrade4, Emilia M Jalil4, Fabio Russomano5, Mônica Derrico4, Valdilea G Veloso4, Ruth K Friedman4, Paula M Luz4, Beatriz Grinsztejn4. 1. Department of Medicine, Division of Infectious Diseases, Program in Global Health, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, CHS 37-121, Los Angeles, CA 90095, USA; Department of Internal Medicine, Montefiore University Hospital of Albert Einstein College of Medicine, Bronx, New York, USA. Electronic address: mcambou@montefiore.org. 2. Virology Laboratory, Instituto de Medicina Tropical, Universidade de São Paulo, São Paulo, SP, Brazil. 3. Department of Medicine, Division of Infectious Diseases, Program in Global Health, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, CHS 37-121, Los Angeles, CA 90095, USA. 4. Instituto Nacional de Infectologia Evandro Chagas (IPEC), Fundação Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, Brazil. 5. Instituto Fernandes Figueira, Fiocruz, Rio de Janeiro, RJ, Brazil.
Abstract
OBJECTIVES: HIV-infected women are at increased risk of human papillomavirus (HPV) infection. Time trends in annual prevalences of cervical high-risk human papillomavirus (HR-HPV) genotypes among a non-vaccinated, HIV-infected female cohort in urban Brazil were assessed for the period 2006-2012. METHODS: Cervical specimens were collected for HPV genotyping yearly between January 2006 and December 2012 in a cross-sectional analysis of participants aged ≥18 years enrolled in the Women's HIV Cohort at Fiocruz in Rio de Janeiro, Brazil. Age-adjusted generalized estimating equation models with an exchangeable matrix were used to estimate odds ratios (OR) and 95% confidence intervals (CI) for annual HPV positivity (reference year: 2006). RESULTS: Among the 590 participants, the median age across all study years ranged from 35.5 to 40.0 years. The prevalence of any HR-HPV was ≥53% every year; prevalences of HR-HPV 16, 58, 59, and 68 were ≥24% in at least 1 year. The odds of HPV 16 and 68 decreased in 2012. HPV 58 prevalence followed a U-shape, beginning and ending at >20%. HPV 59 prevalence followed a linear trend, with increased odds in 2012 (OR 16.0, 95% CI 3.8-67.3; Bonferroni-adjusted p-value <0.01). CONCLUSIONS: The prevalences of HR-HPV 58, 59, and 68 were high in this cohort. Given current HR-HPV vaccine coverage and availability, further investigations are needed to optimize vaccine recommendations for this population.
OBJECTIVES:HIV-infectedwomen are at increased risk of human papillomavirus (HPV) infection. Time trends in annual prevalences of cervical high-risk human papillomavirus (HR-HPV) genotypes among a non-vaccinated, HIV-infected female cohort in urban Brazil were assessed for the period 2006-2012. METHODS: Cervical specimens were collected for HPV genotyping yearly between January 2006 and December 2012 in a cross-sectional analysis of participants aged ≥18 years enrolled in the Women's HIV Cohort at Fiocruz in Rio de Janeiro, Brazil. Age-adjusted generalized estimating equation models with an exchangeable matrix were used to estimate odds ratios (OR) and 95% confidence intervals (CI) for annual HPV positivity (reference year: 2006). RESULTS: Among the 590 participants, the median age across all study years ranged from 35.5 to 40.0 years. The prevalence of any HR-HPV was ≥53% every year; prevalences of HR-HPV 16, 58, 59, and 68 were ≥24% in at least 1 year. The odds of HPV 16 and 68 decreased in 2012. HPV 58 prevalence followed a U-shape, beginning and ending at >20%. HPV 59 prevalence followed a linear trend, with increased odds in 2012 (OR 16.0, 95% CI 3.8-67.3; Bonferroni-adjusted p-value <0.01). CONCLUSIONS: The prevalences of HR-HPV 58, 59, and 68 were high in this cohort. Given current HR-HPV vaccine coverage and availability, further investigations are needed to optimize vaccine recommendations for this population.
Authors: Mary C Cambou; Paula M Luz; Jordan E Lake; José Eduardo Levi; José Ricardo Coutinho; Angela de Andrade; Thais Heinke; Mônica Derrico; Valdilea G Veloso; Ruth K Friedman; Beatriz Grinsztejn Journal: AIDS Patient Care STDS Date: 2015-01 Impact factor: 5.078
Authors: P M Luz; L Velasque; R K Friedman; F Russomano; A C Andrade; R I Moreira; J Chicarino-Coelho; E Pires; V G Veloso; B Grinsztejn Journal: Int J STD AIDS Date: 2012-01 Impact factor: 1.359
Authors: Nathalie Dauphin McKenzie; Erin N Kobetz; James Hnatyszyn; Leo B Twiggs; Joseph A Lucci Journal: Gynecol Oncol Date: 2009-11-10 Impact factor: 5.482
Authors: José V Fernandes; Rosely V Meissner; Maria Gf Carvalho; Thales Aam Fernandes; Paulo Rm Azevedo; João S Sobrinho; José Cm Prado; Luisa L Villa Journal: BMC Res Notes Date: 2010-04-08
Authors: Mélanie Drolet; Élodie Bénard; Marie-Claude Boily; Hammad Ali; Louise Baandrup; Heidi Bauer; Simon Beddows; Jacques Brisson; Julia M L Brotherton; Teresa Cummings; Basil Donovan; Christopher K Fairley; Elaine W Flagg; Anne M Johnson; Jessica A Kahn; Kimberley Kavanagh; Susanne K Kjaer; Erich V Kliewer; Philippe Lemieux-Mellouki; Lauri Markowitz; Aminata Mboup; David Mesher; Linda Niccolai; Jeannie Oliphant; Kevin G Pollock; Kate Soldan; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Marc Brisson Journal: Lancet Infect Dis Date: 2015-03-03 Impact factor: 25.071